An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.
Identifieur interne : 000092 ( PubMed/Curation ); précédent : 000091; suivant : 000093An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.
Auteurs : C. Ansoms [Belgique] ; F. Deckers ; P. Lehert ; I. Pelc ; A. PotgieterSource :
- European addiction research [ 1022-6877 ] ; 2000.
Descripteurs français
- Wicri :
- geographic : Belgique, Luxembourg (pays).
English descriptors
- KwdEn :
- Adult, Alcohol Deterrents (adverse effects), Alcohol Deterrents (therapeutic use), Alcoholism (rehabilitation), Belgium, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Luxembourg, Male, Middle Aged, Psychotherapy, Taurine (adverse effects), Taurine (analogs & derivatives), Taurine (therapeutic use), Treatment Outcome.
- MESH :
- chemical , adverse effects : Alcohol Deterrents, Taurine.
- chemical , analogs & derivatives : Taurine.
- chemical , therapeutic use : Alcohol Deterrents, Taurine.
- geographic : Belgium, Luxembourg.
- rehabilitation : Alcoholism.
- Adult, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychotherapy, Treatment Outcome.
Abstract
This open study on 614 alcohol-dependent patients from 51 centres in Belgium over 24 weeks collected data on the sociodemographic, medical and drug safety profiles and the type of psychosocial support most commonly associated with acamprosate. Psychiatric problems (34%) and gastro-intestinal ulcers (15%) were the most frequent other medical diagnoses. As supportive treatment, 48% of patients received individual psychotherapy, 25% group therapy, 16% relapse prevention and coping skills, 9% brief intervention and 2% family therapy. Fifteen (29%) centres used only 1 form of supportive treatment, 14 (27%) used 2 forms of support, 16 (31%) used 3 forms, 4 (8%) used 4 and only 2 centres (4%) used all 5 supportive treatment options. Three hundred and fifty-nine patients dropped out of the study. At any moment during the treatment period, up to 11% relapsed, 9% had binge drinking and 9% had drinking lapses. The quantity of alcohol consumption during relapse, lapse or binge drinking showed a considerable drop in the mean number of drinks per day, from 19.53 before treatment to 4.23-7.83 drinks for lapse drinking, 9.27-14.62 drinks for binge drinking and 4.96-10.29 drinks per day for relapse. All 8 dimensions of the SF36 quality of life questionnaire improved over the treatment period. Acamprosate was well tolerated by all patients.
DOI: 19025
PubMed: 11060477
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000092
Links to Exploration step
pubmed:11060477Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.</title><author><name sortKey="Ansoms, C" sort="Ansoms, C" uniqKey="Ansoms C" first="C" last="Ansoms">C. Ansoms</name><affiliation wicri:level="1"><nlm:affiliation>Kliniek Broeders Alexianen, Tienen, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Kliniek Broeders Alexianen, Tienen</wicri:regionArea></affiliation></author><author><name sortKey="Deckers, F" sort="Deckers, F" uniqKey="Deckers F" first="F" last="Deckers">F. Deckers</name></author><author><name sortKey="Lehert, P" sort="Lehert, P" uniqKey="Lehert P" first="P" last="Lehert">P. Lehert</name></author><author><name sortKey="Pelc, I" sort="Pelc, I" uniqKey="Pelc I" first="I" last="Pelc">I. Pelc</name></author><author><name sortKey="Potgieter, A" sort="Potgieter, A" uniqKey="Potgieter A" first="A" last="Potgieter">A. Potgieter</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:11060477</idno><idno type="pmid">11060477</idno><idno type="doi">19025</idno><idno type="wicri:Area/PubMed/Corpus">000092</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000092</idno><idno type="wicri:Area/PubMed/Curation">000092</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000092</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.</title><author><name sortKey="Ansoms, C" sort="Ansoms, C" uniqKey="Ansoms C" first="C" last="Ansoms">C. Ansoms</name><affiliation wicri:level="1"><nlm:affiliation>Kliniek Broeders Alexianen, Tienen, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Kliniek Broeders Alexianen, Tienen</wicri:regionArea></affiliation></author><author><name sortKey="Deckers, F" sort="Deckers, F" uniqKey="Deckers F" first="F" last="Deckers">F. Deckers</name></author><author><name sortKey="Lehert, P" sort="Lehert, P" uniqKey="Lehert P" first="P" last="Lehert">P. Lehert</name></author><author><name sortKey="Pelc, I" sort="Pelc, I" uniqKey="Pelc I" first="I" last="Pelc">I. Pelc</name></author><author><name sortKey="Potgieter, A" sort="Potgieter, A" uniqKey="Potgieter A" first="A" last="Potgieter">A. Potgieter</name></author></analytic><series><title level="j">European addiction research</title><idno type="ISSN">1022-6877</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Alcohol Deterrents (adverse effects)</term><term>Alcohol Deterrents (therapeutic use)</term><term>Alcoholism (rehabilitation)</term><term>Belgium</term><term>Combined Modality Therapy</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Luxembourg</term><term>Male</term><term>Middle Aged</term><term>Psychotherapy</term><term>Taurine (adverse effects)</term><term>Taurine (analogs & derivatives)</term><term>Taurine (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Alcohol Deterrents</term><term>Taurine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Taurine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Alcohol Deterrents</term><term>Taurine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Belgium</term><term>Luxembourg</term></keywords><keywords scheme="MESH" qualifier="rehabilitation" xml:lang="en"><term>Alcoholism</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Combined Modality Therapy</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Psychotherapy</term><term>Treatment Outcome</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Belgique</term><term>Luxembourg (pays)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This open study on 614 alcohol-dependent patients from 51 centres in Belgium over 24 weeks collected data on the sociodemographic, medical and drug safety profiles and the type of psychosocial support most commonly associated with acamprosate. Psychiatric problems (34%) and gastro-intestinal ulcers (15%) were the most frequent other medical diagnoses. As supportive treatment, 48% of patients received individual psychotherapy, 25% group therapy, 16% relapse prevention and coping skills, 9% brief intervention and 2% family therapy. Fifteen (29%) centres used only 1 form of supportive treatment, 14 (27%) used 2 forms of support, 16 (31%) used 3 forms, 4 (8%) used 4 and only 2 centres (4%) used all 5 supportive treatment options. Three hundred and fifty-nine patients dropped out of the study. At any moment during the treatment period, up to 11% relapsed, 9% had binge drinking and 9% had drinking lapses. The quantity of alcohol consumption during relapse, lapse or binge drinking showed a considerable drop in the mean number of drinks per day, from 19.53 before treatment to 4.23-7.83 drinks for lapse drinking, 9.27-14.62 drinks for binge drinking and 4.96-10.29 drinks per day for relapse. All 8 dimensions of the SF36 quality of life questionnaire improved over the treatment period. Acamprosate was well tolerated by all patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11060477</PMID><DateCreated><Year>2001</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2001</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1022-6877</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European addiction research</Title><ISOAbbreviation>Eur Addict Res</ISOAbbreviation></Journal><ArticleTitle>An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.</ArticleTitle><Pagination><MedlinePgn>132-40</MedlinePgn></Pagination><Abstract><AbstractText>This open study on 614 alcohol-dependent patients from 51 centres in Belgium over 24 weeks collected data on the sociodemographic, medical and drug safety profiles and the type of psychosocial support most commonly associated with acamprosate. Psychiatric problems (34%) and gastro-intestinal ulcers (15%) were the most frequent other medical diagnoses. As supportive treatment, 48% of patients received individual psychotherapy, 25% group therapy, 16% relapse prevention and coping skills, 9% brief intervention and 2% family therapy. Fifteen (29%) centres used only 1 form of supportive treatment, 14 (27%) used 2 forms of support, 16 (31%) used 3 forms, 4 (8%) used 4 and only 2 centres (4%) used all 5 supportive treatment options. Three hundred and fifty-nine patients dropped out of the study. At any moment during the treatment period, up to 11% relapsed, 9% had binge drinking and 9% had drinking lapses. The quantity of alcohol consumption during relapse, lapse or binge drinking showed a considerable drop in the mean number of drinks per day, from 19.53 before treatment to 4.23-7.83 drinks for lapse drinking, 9.27-14.62 drinks for binge drinking and 4.96-10.29 drinks per day for relapse. All 8 dimensions of the SF36 quality of life questionnaire improved over the treatment period. Acamprosate was well tolerated by all patients.</AbstractText><CopyrightInformation>Copyright 2000 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ansoms</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Kliniek Broeders Alexianen, Tienen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckers</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lehert</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pelc</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Potgieter</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Addict Res</MedlineTA><NlmUniqueID>9502920</NlmUniqueID><ISSNLinking>1022-6877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000427">Alcohol Deterrents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1EQV5MLY3D</RegistryNumber><NameOfSubstance UI="D013654">Taurine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N4K14YGM3J</RegistryNumber><NameOfSubstance UI="C043877">acamprosate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000427" MajorTopicYN="N">Alcohol Deterrents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008189" MajorTopicYN="N" Type="Geographic">Luxembourg</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013654" MajorTopicYN="N">Taurine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>4</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>4</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11060477</ArticleId><ArticleId IdType="pii">19025</ArticleId><ArticleId IdType="doi">19025</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000092 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000092 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= TherFamFrancoV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:11060477
|texte= An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:11060477" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a TherFamFrancoV1
| This area was generated with Dilib version V0.6.29. |  |